EUCTR2014-000179-18-GB进行中（未招募）1 期
ocal Oestrogen Treatment in Postmenopausal Women Undergoing Pelvic Organ Prolapse Surgery (LOTUS) - Feasibility Study - LOTUS
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Postmenopausal women
- •2.Consented to undergo surgical intervention for pelvic organ prolapse
- •3.Have not received HRT in the last 12 months
- •4.Willing to be randomised
- •5.Give written informed consent
- •Are the trial subjects under 18?
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1. Previous breast or uterine malignancy or other hormone- dependent neoplasms
- •2. Genital bleeding of unknown origin
- •3. Previous thrombo-embolic episodes in relation to oestrogen therapy
- •4. Women who cannot understand speak or write in English
- •5. Women known to be allergic to any of the components of vaginal oestrogens
- •6. Two or more episodes of culture positive UTI in the last 6 months
- •7. Previous POP surgery
- •8. Voiding dysfunction(PVR>150ml)
- •9. Current or previous POP surgery involving mesh
研究者
相似试验
已完成
不适用
ocal oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgeryISRCTN46661996Birmingham & Black Country (University Hospital Birmingham NHS Foundation Trust)100
进行中（未招募）
不适用
eoadjuvant hormone therapy for postmenopausal women with ER and/or PgR positive primary breast cancer: A multi-center study to determine the optimum length of treatment with Femara (letrozole 2.5mg daily) on tumour regression to permit breast conserving surgery.Postmenopausal women with ER and/or PgR positive primary breast cancerEUCTR2005-000661-19-GBovartis Pharmaceuticals UK Ltd
已完成
不适用
PREOPERATIVE TREATMENT OF POSTMENOPAUSAL BREAST CANCER PATIENTS WITH LETROZOLE: A RANDOMIZED DOUBLE-BLIND MULTICENTER STUDYPER-019-99OVARTIS BIOSCIENSES PERÚ S.A.,
进行中（未招募）
不适用
eoadjuvant therapy for postmenopausal women with ER and/or PgR positive breast cancer. A randomized open phase II trial evaluating the efficacy of a 6 months preoperative treatment withLetrozole (2.5 mg/day) with or withoutZoledronic acid (4 mg every 4 weeks). - FEMZONEEUCTR2004-004007-37-DEovartis Pharma GmbH
招募中
不适用
Effects of Testosterone and Oestradiol Therapy on Clinical Indices and Biomarkers of Dry Eye in Post Menopausal WomeEye - Diseases / disorders of the eyeDry EyeACTRN12612000281897School of Optometry and Vision Science80